Startups

Beacon Biosignals

Boston, Massachusetts

beacon.bio

AI-driven brain-health insights and FDA-cleared Waveband home EEG.

Founded 2019

Team

Andrew BeckBoard Member

Gaurav SingalBoard Member

Jacob DonoghueCEO and Co-Founder

Jarrett RevelsCTO and Co-Founder

Sydney CashCo-Founder

Investments

$11M2026-04-06	Hemant Taneja
$11M2026-04	Anthony Philippakis, Hemant Taneja, JSL Health, Palo Santo VC, Daniel Goldberg, Kicker Ventures, Samsung Next, GV
$86M2025-11-13	GV, Hemant Taneja
$86M2025-11	Anthony Philippakis, Hemant Taneja, GV, Innoviva, Nexus NeuroTech Ventures, S32, Catalio Capital Management, Takeda, General Catalyst, Caitlin Donovan, Logos Capital, Casdin Capital, Indicator Ventures, Alumni Ventures, Synetro Group, Iaso Ventures
$27M2021-11-08	General Catalyst, Hemant Taneja, Andrew Beck, Gaurav Singal, Arif Nathoo, Casdin Capital

team@apexlogos.ai22 days ago
RELATED
team@apexlogos.ai27 days ago
Research note — Beacon Biosignals (id BeaconBiosignals). Clinical wearable EEG + AI biomarkers for CNS trials and home sleep testing; not consumer telepathy. Listings - Fast Company Most Innovative Companies of 2026 (company news 2026-03-24; Fast Company medical-devices list https://www.fastcompany.com/91497257/medical-devices-most-innovative-companies-2026). - Nasdaq Times Square celebration of the $86M close (company 2025 year-in-review LinkedIn). Funding (do not collapse into a single $97M round — existing companyText rows are $86M + $11M) - Seed ~$3M implied: Series A PR says $27M A brings total to $30M. Named seed/angel participants on company LinkedIn 2021-11-08: Andrew Beck, Gaurav Singal, Arif Nathoo. PitchBook also shows a $50k individual angel on 2019-02-07 (unnamed here). - Series A 2021-11-08 USD 27,000,000 (roundId 10553), led by General Catalyst (Hemant Taneja credited as GC representative from Donoghue’s thank-you post); Casdin Capital participated. Angels: Andrew Beck (PathAI CEO; PR-named), Gaurav Singal, Arif Nathoo (company LinkedIn). Robin Washington joined the board (not recorded as a check). - Series B 2025-11 USD 86,000,000 (existing roundId 574, companyText "Beacon Biosignals"). Official PR syndicate: Innoviva, GV, Nexus NeuroTech Ventures, S32, Catalio Capital Management, Takeda; continued support from General Catalyst, Logos Capital, Casdin Capital, Indicator Ventures. CEO LinkedIn 2025-11-14 additionally names Alumni Ventures, Synetro Group, Iaso Ventures. Anthony Philippakis (GV GP) is quoted — credited to GV investorId 1582 with roleId 15, not as a personal angel. Caitlin Donovan (GC Partner, on Beacon’s board) credited on GC’s B participation. - Series B extension 2026-04 USD 11,000,000 (existing roundId 573; 86+11=97). Official PR 2026-04-06: upsize to $97M, cumulative funding over $132M. New investors only: JSL Health, Palo Santo VC, Kicker Ventures, Samsung Next. Daniel Goldberg (Palo Santo MD) is quoted — credited to Palo Santo VC with roleId 16, not as a personal angel. Tomoko Ishikura’s Signal “Investor Beacon Biosignals” line was not treated as a personal check; Kicker is the firm. GV also attached to round 573 because the pre-existing Anthony Philippakis companyText row sat on his personal investorId; source is GV as firm. MIT sleep mapping (https://news.mit.edu/2026/beacon-biosignals-maps-brain-during-sleep-0501, 2026-05-01) - Founded 2019 by Jake Donoghue PhD ’19 (CEO) and former MIT Julia Lab researcher Jarrett Revels (CTO). Mentors Sydney Cash and Brandon Westover (HST / HMS); company LinkedIn Series A post names all four as founders. Lightweight EEG headband measures brain activity during normal at-home sleep; ML for treatment effects, disease-progression signs, trial cohorts. FDA 510(k)-cleared device used in 40+ global trials (MDD, schizophrenia, narcolepsy, idiopathic hypersomnia, Alzheimer’s, Parkinson’s). Donoghue: “step-change” when clinical-grade EEG leaves the sleep lab. Building a “foundation model” of the brain from a dataset “that doesn’t exist yet — but we are rapidly creating it.” MIT article’s “November $97M” line is the B + later upsize, not a separate round. Clinical vs consumer - Company FAQ and Series B PR: consumer wearables infer sleep from HR/movement; Beacon’s Waveband (formerly Dreem 3S) directly measures EEG during sleep and wake. Positioning is pharma trials (Phase 1–4) plus physician-ordered home sleep testing after the CleveMed acquisition — not consumer BCI / telepathy. Neurofounders 2026-09-07 webinar (Arctop vs Piramidal) is adjacent market context, not a Beacon interview. Dataset / foundation-model claims - Homepage: “world’s largest clinically validated neurophysiology dataset”; 2M+ hours of EEG analyzed; 40+ trials; 500K home sleep tests. - Series B PR: foundation model of brain activity trained on millions of hours of EEG to uncover early disease signatures and predict treatment response. - Sleep as window into depression, Parkinson’s, Alzheimer’s, sleep apnea; longitudinal record so an HST today can become a pre-symptomatic biomarker later. Team (about page https://beacon.bio/about) - Founders recorded: Jacob Donoghue CEO & Co-Founder (investorId 3296, roleId 3040); Jarrett Revels CTO & Co-Founder (3297, 3041); Sydney Cash Co-Founder (3299, 3044). Brandon Westover / M. Brandon Westover is a co-founder on company LinkedIn, Equilar, and Donoghue interviews, but no unique LinkedIn/X was found so no person record was created. - Leadership not added as investor records: Matt Alkaitis CCO; David Matthews CBO; Alex Chan VP Analytics/ML (ex-Apple Watch sleep); Allison Braly VP Clinical Strategy; Craig Gallivan VP Clinical Sales; Emily Mitchell VP Clinical Study Ops; Hani Kayyali VP Diagnostics (ex-CleveMed CEO); Ilan Goodman VP Platform; Leticia Soto VP Quality; Sarah Weimer VP Sleep Services; Tahir Rizvi VP Regulatory; Yongbo Wang VP Hardware. - Board (about): Caitlin Donovan (GC Partner — reused); Naveen Rao (former MosaicML CEO); Pavel Raifeld (Innoviva CEO, quoted on B). Equilar also lists Andrew Beck and Gaurav Singal as Beacon board members (roles added). Robin Washington joined at Series A (not re-confirmed on the current about page). Materials / other - CleveMed HST acquisition announced 2025-04-21 (undisclosed price); SleepView / SleepView Direct; Cleveland office; MIT says the acquired HST business served 100k+ US patients/year. - Takeda collaboration expansion 2025-11-19: up to $109M data-license fees and milestones “including equity participation” (commercial + possible equity, not a priced VC round). - Harmony Biosciences partnership 2025-12-16 (qEEG endpoints in hypersomnia) — not an investment. - HQ Boston; historical addresses 80 Revere St #10 and 22 Boston Wharf Rd Floor 7 appear in directories. Schema gaps / not modeled - Round schema cannot represent an upsize of an existing round; $97M is 86+11 on two dates. No round “stage” field (Series A/B). - No valuation, no per-investor check sizes, no cap table. Seed investors besides the three named angels are undisclosed. - Acquisitions (CleveMed) have no consideration field. Commercial partnerships with equity (Takeda $109M) and pharma logos (UCB, Syndeio, Mineralys, Novartis, Lundbeck, Harmony) are not investments. - Device 510(k) / PCCP regulatory status, Waveband rename, CPT reimbursement, and “foundation model” claims have no schema. - Listings (Fast Company) have no field. - PitchBook names Half Court Ventures among 18 investors; no primary PR confirmation, not added. Tracxn’s Quentin Soulet as co-founder/CTO conflicts with Jarrett Revels and was not added. - Daniel Goldberg / Palo Santo: credited as firm only. Anthony Philippakis: credited as GV firm, not personal. Takeda is both a Series B investor (PR) and a commercial partner.